Ocugen (OCGN)
(Delayed Data from NSDQ)
$1.63 USD
-0.08 (-4.68%)
Updated May 29, 2024 04:00 PM ET
Pre-Market: $1.61 -0.02 (-1.23%) 9:26 AM ET
2-Buy of 5 2
F Value C Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
OCGN 1.63 -0.08(-4.68%)
Will OCGN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for OCGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OCGN
Is Bicycle Therapeutics (BCYC) Outperforming Other Medical Stocks This Year?
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
OCGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
Ocugen Q2 Preview: Rebound Quarter Inbound?
Implied Volatility Surging for Ocugen (OCGN) Stock Options
Other News for OCGN
Ocugen to Present at BIO International Convention 2024
Ocugen Inc. stock falls Wednesday, underperforms market
Ocugen Set to Join Russell 3000® Index Effective June 28, 2024
Ocugen set to join Russell 3000 Index
Ocugen set to join Russell 3000 Index